Skip to main content
. 2004 Jul 10;54(2):172–178. doi: 10.1007/s00262-004-0575-z

Table 6.

Distribution of HLA-Bw4Ile80and HLA-Bw4Thr80 ligands in KIR3DL1/HLA-Bw4 positive patients (n=24) and controls (n=33)

  Bw4Ile80 Bw4Ile80;Thr80 Bw4Thr80
Patients 17 (70.8%) 1 (4.2%) 6 (25.0%)
 Primary MM 7 (29.2%) 1 (4.2%) 5 (20.8%)
 Metastatic MM 10 (41.6%) 0 1 (4.2%)
Controls 26 (78.8%) 2 (6.0%) 5 (15.2%)